Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Single-Arm Study of Ropeginterferon alfa-2b (P1101) in Adult T-cell Leukemia/Lymphoma
jRCT2071240011Phase 2Recruiting
- Sponsor
- PharmaEssentia
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ropeginterferon alfa-2b in adult T-cell leukemia-lymphoma (ATLL), sponsored by PharmaEssentia. Primary endpoint: Response Proportion. Started Jun 2024; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2071240011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240011.